Walden Wealth Partners’s AbbVie ABBV Stock Holding History

Walden Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$245K	Hold	1,430	–	–	0.14%	73
2024 Q1	$240K	Hold	1,430	–	–	0.14%	79
2023 Q4	$222K	Buy	+1,430	New	+$208K	0.14%	82

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Walden Wealth Partners's ABBV Position: Q2 2024 in Review

Walden Wealth Partners held its AbbVie (ABBV) position steady in Q2 2024 at 1,430 shares worth $245K. The position accounts for 0.14% of the portfolio, ranked #73.

Walden Wealth Partners first reported a position in ABBV in Q4 2023 and has held it in 3 quarters since. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Walden Wealth Partners held 1,430 shares of AbbVie worth $245K as of Q2 2024.
Walden Wealth Partners left its AbbVie share count unchanged in Q2 2024.
AbbVie made up 0.14% of Walden Wealth Partners's portfolio in Q2 2024, its #73 holding.
Walden Wealth Partners first reported a position in AbbVie in Q4 2023 and has held it in 3 quarters since.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Walden Wealth Partners's 13F filing for Q2 2024, filed 11 Jul 2024.